The in Vitro Phosphorylation of P53 by Calcium-dependent Protein Kinase C--characterization of a Protein-kinase-C-binding Site on P53
Overview
Affiliations
We show that, in vitro, Ca2+-dependent protein kinase C (PKC) phosphorylates recombinant murine p53 protein on several residues contained within a conserved basic region of 25 amino acids, located in the C-terminal part of the protein. Accordingly, synthetic p53-(357-381)-peptide is phosphorylated by PKC at multiple Ser and Thr residues, including Ser360, Thr365, Ser370 and Thr377. We also establish that p53-(357-381)-peptide at micromolar concentrations has the ability to stimulate sequence-specific DNA binding by p53. That stimulation is lost upon phosphorylation by PKC. To further characterise the mechanisms that regulate PKC-dependent phosphorylation of p53-(357-381)-peptide, the phosphorylation of recombinant p53 and p53-(357-381)-peptide by PKC were compared. The results suggest that phosphorylation of full-length p53 on the C-terminal PKC sites is highly dependent on the accessibility of the phosphorylation sites and that a domain on p53 distinct from p53-(357-381)-peptide is involved in binding PKC. Accordingly, we have identified a conserved 27-amino-acid peptide, p53-(320-346)-peptide, within the C-terminal region of p53 and adjacent to residues 357-381 that interacts with PKC in vitro. The interaction between p53-(320-346)-peptide and PKC inhibits PKC autophosphorylation and the phosphorylation of substrates, including p53-(357-381)-peptide, neurogranin and histone H1. Conventional Ca2+-dependent PKC alpha, beta and gamma and the catalytic fragment of PKC (PKM) were nearly equally susceptible to inhibition by p53-(320-346)-peptide. The Ca2+-independent PKC delta was much less sensitive to inhibition. The significance of these findings for understanding the in vivo phosphorylation of p53 by PKC are discussed.
Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
Ho D, Kim H, Kim J, Sim H, Ahn H, Kim J Mol Brain. 2015; 8:54.
PMID: 26384650 PMC: 4575451. DOI: 10.1186/s13041-015-0145-7.
Jiang Z, Kong C, Zhang Z, Zhu Y, Zhang Y, Chen X J Cell Mol Med. 2015; 19(5):1085-93.
PMID: 25752336 PMC: 4420610. DOI: 10.1111/jcmm.12503.
Allosteric modulation of protein oligomerization: an emerging approach to drug design.
Gabizon R, Friedler A Front Chem. 2014; 2:9.
PMID: 24790978 PMC: 3982530. DOI: 10.3389/fchem.2014.00009.
Role of p53 in Cell Death and Human Cancers.
Ozaki T, Nakagawara A Cancers (Basel). 2013; 3(1):994-1013.
PMID: 24212651 PMC: 3756401. DOI: 10.3390/cancers3010994.
Smith S, Enge M, Bao W, Thullberg M, Costa T, Olofsson H J Biol Chem. 2012; 287(35):29336-47.
PMID: 22773839 PMC: 3436133. DOI: 10.1074/jbc.M112.341917.